Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have underperformed the market over the last 12 months.

During this time, the biotechnology giant's shares have fallen 2%.

As a comparison, the ASX 200 index has risen approximately 12% over the same period.

Is this underperformance a buying opportunity or should you keep your powder dry for the time being? Let's see what analysts are saying about the company this month.

Are CSL shares a buy?

With earnings season now well and truly behind us, analysts have updated their financial models and recommendations accordingly.

The good news for shareholders (and potential investors) is that the general consensus is that CSL shares are meaningfully undervalued at current levels.

For example, no fewer than six major brokers have the equivalent of buy ratings on the company's shares with price targets that imply double-digit returns for investors buying at current prices.

One of those brokers is Jefferies, which currently has a buy rating and $338.50 price target on CSL's shares. This implies potential upside of 21% for investors from current levels.

Elsewhere, the team at UBS remains positive on CSL. It responded to the company's half year results lat month by retaining its buy rating with a $330.00 price target. This suggests that its shares could rise a very attractive 18% over the next 12 months.

Anyone else?

Over at Morgans, its analysts are fans of CSL. In fact, they are so positive they have named the company on their best ideas list once again this month. They explain:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans currently has an add rating and $315.40 price target, which offers potential upside of approximately 13%.

Even Citi, which downgraded CSL's shares to a neutral rating last month, has a price target of $305.00, which offers decent 9% upside for investors.

Overall, the broker community appears to see the risk/reward on offer with CSL shares as quite compelling based on where they trade today.

But as always, time will tell if these analysts are on the money with their recommendations with this one.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A women has her eyes checked at the optometrist.
Healthcare Shares

Is Medibank stock a good buy?

Can this company provide healthy returns?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »